期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 20, 期 10, 页码 2675-2685出版社
WILEY
DOI: 10.1111/ajt.15881
关键词
alloantibody; B cell biology; costimulation; desensitization; immunobiology; immunosuppression; immune modulation; kidney transplantation; nephrology; translational research; science
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [1R01AI110513, P01AI-97113]
- NIH Respiratory Biology Training Grant T32 [HL07605]
- American Heart Association and Enduring Hearts [15POST25700452]
Active antibody-mediated rejection (AMR) is a potentially devastating complication and consistently effective treatment remains elusive. We hypothesized that the reversal of acute AMR requires rapid elimination of antibody-secreting plasma cells (PC) with a proteasome inhibitor, bortezomib, followed by the sustained inhibition of PC generation with CTLA4-Ig or belatacept (B/B). We show in mice that B/B therapy selectively depleted mature PC producing donor-specific antibodies (DSA) and reduced DSA, when administered after primary and secondary DSA responses had been established. A pilot investigation was initiated to treat six consecutive patients with active AMR with B/B. Compassionate use of this regimen was initiated for the first patient who developed early, severe acute AMR that did not respond to steroids, plasmapheresis, and intravenous immunoglobulin after his third kidney transplant. B/B treatment resulted in a rapid reversal of AMR, leading us to treat five additional patients who also resolved their acute AMR episode and had sustained disappearance of circulating DSA for <= 30 months. This study provides a proof-of-principle demonstration that mouse models can identify mechanistically rational therapies for the clinic. Follow-up investigations with a more stringent clinical design are warranted to test whether B/B improves on the standard of care for the treatment of acute AMR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据